No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XGN240719C2500
- 0.02
- -0.23-92.00%
15min DelayClose Jul 19 15:56 ET
0.05High0.02Low
0.05Open0.25Pre Close59 Volume2 Open Interest2.50Strike Price280.00Turnover1876.29%IV28.57%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.1183Delta0.5309Gamma98.00Leverage Ratio-0.9664Theta0.0000Rho11.59Eff Leverage0.0000Vega
Intraday
- 5D
- Daily
News
Exagen(XGN.US) Officer Buys US$77,569.92 in Common Stock
$Exagen(XGN.US)$ Officer ABALLI JOHN purchased 40,401 shares of common stock on May 16, 2024 at an average price of $1.92 for a total value of $77,569.92.Source: Announcement What is statement of chan
Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7
Exagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 326.83% Cantor Fitzgerald $5 → $7 Maintains Overweight 09/26/2023 265.85% Cantor Fitzgerald → $
Comments
Analysts predict Exagen's revenue growth to decelerate significantly, with an expected annual growth of 3.1% till 2024, compared to its past five-year growth rate of 7.5%. This is slower than the projected 18% annual growth of its industry peers.
The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New Forecasts 2
The low P/S ratio and slower revenue growth have led to pessimism among shareholders about the company's future prospects. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
1
$Exagen(XGN.US$ estimates beat!
Exagen's low P/S ratio indicates investor concerns over below-average expected revenue growth. For a higher P/S ratio or share price, conditions would need to improve. The recent drop in share price may be due to this potentially less favorable outlook.
Read more